WCBA
SLXP

Weaver C. Barksdale & Associates’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-30
Closed -$5K – 581
2015
Q1 		$5K Sell
30
-25
-45% -$3.67K ﹤0.01% 405
2014
Q4 		$6K Sell
55
-16,681
-100% -$2.02M ﹤0.01% 366
2014
Q3 		$2.62M Sell
16,736
-2,910
-15% -$422K 2.15% 2
2014
Q2 		$2.42M Buy
19,646
+19,610
+54,472% +$2.17M 1.95% 20
2014
Q1 		$4K Sell
36
-13
-27% -$1.33K ﹤0.01% 430
2013
Q4 		$4K Hold
49
– – ﹤0.01% 428
2013
Q3 		$3K Buy
+49
New +$3.38K ﹤0.01% 484

Other funds holding SLXP

MMG
Monetary Management Group St Louis, Missouri $419M AUM 29.55% 1-Year Est. Return

Weaver C. Barksdale & Associates's SLXP Position: Q2 2015 in Review

Weaver C. Barksdale & Associates sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 30 shares — an estimated $5K sold.

Weaver C. Barksdale & Associates first reported a position in SLXP in Q3 2013 and held it in 7 quarters. The position peaked at $2.62M in Q3 2014. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

  • Weaver C. Barksdale & Associates reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
  • Weaver C. Barksdale & Associates sold 30 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $5K.
  • Weaver C. Barksdale & Associates first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2013 and held it in 7 quarters.
  • Weaver C. Barksdale & Associates's SALIX PHARMACEUTICALS LTD DEL position peaked at $2.62M in Q3 2014.
  • 1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2015, filed 17 Jul 2015.